Scientists at deCODE genetics and collaborators have published a study in the Journal of Allergy and Clinical Immunology ...
Scientists at deCODE genetics, a subsidiary of Amgen, and collaborators have published a study in Journal of Allergy and ...
Balancing bold ideas and financial challenges: Dr. Amali Samarasinghe's resilient journey to success
Amali Samarasinghe, PhD, associate professor in the Department of Pediatrics at UT Health Science Center, describes herself as an aficionada of the alternative hypothesis. “I have a passion to uncover ...
Scientists at deCODE genetics, a subsidiary of Amgen, and collaborators have published a study in Journal of Allergy and ...
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. <li /> Consistent improve ...
The following is a summary of “Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma ...
Eupraxia Pharma reports positive data from RESOLVE phase 1b/2a trial of EP-104GI for treatment of eosinophilic esophagitis: Victoria, British Columbia Thursday, November 14, 2024, ...
Mepolizumab is efficacious in patients with specific phenotypes of severe asthma characterized by persistent, glucocorticosteroid-resistant eosinophilia. Reslizumab may also prove to be ...
the mean reduction in Peak Eosinophil Counts was 83% at 12 weeks. Plasma fluticasone levels continue to be predictable and well-below published levels of daily fluticasone asthma treatments. The ...
Based on the type and number of inflammatory cells in induced sputum, asthma is categorized into four inflammatory phenotypes: eosinophilic, neutrophilic, mixed granulocytic, and paucigranulocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback